A Phase 3 interventional study of Azacitidine and Pevonedistat in Myelodysplastic Syndrome, Leukemia, Myelomonocytic, Chronic and Leukemia, Myeloid, Acute, sponsored by Takeda. Completed at 242 sites in 20 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-10-29.
Sponsored by Takeda · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 130 studies testing azacitidine in Myelodysplastic Syndromes — 13 open to participants now, 25 under way, 3 of them phase 3. Azacitidine · Myelodysplastic Syndromes.
Among the 130 studies testing azacitidine in Myelodysplastic Syndromes, this one is the 2nd largest by enrollment of the 126 interventional ones that give a count, is one of 7 that started in 2017, is one of 9 in phase 3, and was the 94th registered.
1,997 studies on the registry are indexed under Myelodysplastic Syndromes; 324 are open to participants now.
Browse Myelodysplastic Syndromes studies →13 of the 130 studies testing azacitidine in Myelodysplastic Syndromes are open now, in 12 countries. Recruiting first, the newest first:
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine · Sites in China
Ages 18–70
City of Hope Medical Center · Sites in United States
Ages 18–75
Medical College of Wisconsin · Sites in United States
Ages 18+
Institut de Recherches Internationales Servier · Sites in United States, Australia, Brazil and 7 more countries
Ages 18+
Beijing 302 Hospital · Sites in China
Ages 18–70
By country, each count listing its studies:
Azacitidine: first FDA approval 2004 (VIDAZA), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →
Of the 264 Myelodysplastic Syndromes studies recruiting now, 167 (63%) set no upper age limit and 70 (27%) stop at 75 or younger; 57 take children under 18; 17 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
130 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 50 · Phase 2 86 · Phase 3 12 · Phase 4 3
First in 2000; this study’s year is marked. 7 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 454 is above the median of 40 across 1,611 interventional studies indexed under Myelodysplastic Syndromes.
Median enrollment 38 across the 126 interventional studies. Of the 88 that completed or were terminated, 42 (48%) have results posted.
This tab as a report to print or save as PDF → With an account.
32 of 130 have an industry lead sponsor. The 10 most frequent:
Takeda is the lead sponsor of 1,026 studies on the registry; 88 are open to participants now.
Of its 178 completed or terminated interventional studies of FDA-regulated products, 154 (87%) have results posted.
13 studies in Myelodysplastic Syndromes by Takeda: 4 open now, 4 under way, 2 of them phase 3. Of 7 finished, 4 (57%) have results posted.
Among the 13 studies in Myelodysplastic Syndromes by Takeda, this one has the largest enrollment of the 12 interventional ones that give a count, is the only one that started in 2017, is one of 3 in phase 3, and was the 6th registered.
Takeda’s Myelodysplastic Syndromes studies by the year they started, since 2002.
9 of the studies testing azacitidine in Myelodysplastic Syndromes that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06465953Phase 3Institut de Recherches Internationales ServierIvosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Patients With Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) With an IDH1 Mutation | 2027-11-01 |
| NCT05788679Karolinska University HospitalA Study Using Subject-specific MRD to Adopt Treatment After HSCT for Subjects With MDS | 2026-12 |
| NCT00392353National Cancer Institute (NCI)Vorinostat and Azacitidine in Treating Patients With Myelodysplastic Syndromes or Acute Myeloid Leukemia | 2026-12-31 |
| NCT06502145Medical College of WisconsinIadademstat With Hypomethylating Agent in Patients With Myelodysplastic Syndrome | 2026-12-31 |
| NCT03862157M.D. Anderson Cancer CenterAzacitidine, Venetoclax, and Pevonedistat in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia | 2027-01-31 |
Add all 9 to your calendar (.ics) → With an account.
Among the 130 studies testing azacitidine in Myelodysplastic Syndromes, from their registry updates:
Among Takeda’s 13 in Myelodysplastic Syndromes:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine whether the combination of pevonedistat and azacitidine improves event-free survival (EFS) when compared with single-agent azacitidine. (An event is defined as death or transformation to AML in participants with MDS or CMML, whichever occurs first, and is defined as death in participants with low-blast AML).
The drug being tested in this study is called pevonedistat. Pevonedistat is being tested to treat people with higher-risk myelodysplastic syndromes (HR MDS), chronic myelomonocytic leukemia (CMML) and low-blast acute myelogenous leukemia (AML) as a combination treatment with azacitidine. This study will look at the overall survival, event-free survival and response to treatment in people who take pevonedistat and azacitidine when compared to people who take single-agent azacitidine.
The study will enroll approximately 450 participants. Once enrolled, participants will be randomly assigned in 1:1 ratio (by chance, like flipping a coin) to one of the two treatment groups in 28-day treatment cycles:
All participants will receive azacitidine via intravenous or subcutaneous route. Participants randomized to the combination arm will also receive pevonedistat intravenous infusion.
This multi-center trial will be conducted Spain, Belgium, Brazil, Canada, Czech Republic, France, Germany, Israel, Italy, the United States, Australia, Greece, Japan, Mexico, Poland, Russia, Korea, Turkey, China and United Kingdom. The overall time to participate in this study is approximately 63 months. Participants will attend the end-of-treatment visit 30 days after the last dose of study drug or before the start of subsequent anti-neoplastic therapy if that occurs sooner.
Participants with HR MDS or CMML will have EFS follow-up study visits every month if their disease has not transformed to AML and they have not started subsequent therapy. Participants with low-blast AML will have response follow-up study visits every month until they relapse from CR or meet the criteria for PD. All participants will enter OS follow-up (contacted every 3 months) when they have confirmed transformation to AML (for participants with HR MDS or CMML at enrollment) or experienced PD (for participants with low-blast AML at study enrollment).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Has MDS or CMML and must also have one of the following Prognostic Risk Categories, based on the Revised International Prognostic Scoring System (IPSS-R):
Calculation of TRM score:
Exclusion Criteria:
Is eligible for intensive chemotherapy and/or stem cell transplantation. The reason a participant is not eligible for intensive chemotherapy and/or allogeneic stem cell transplantation may consist of one or more of the following factors:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants were administered azacitidine 75 milligram per square meter (mg/m\^2) intravenous (IV) or subcutaneous (SC) injection on Days 1 to 5, Days 8 and 9, in 28-day treatment cycles until disease progression or unacceptable toxicity or up to a maximum of 63 cycles.
Drug: Azacitidine
Participants were administered azacitidine 75 mg/m\^2 IV or SC injection on Days 1 to 5, Days 8 and 9 and pevonedistat 20 mg/m\^2 IV infusion, on Days 1, 3, and 5 in 28-day treatment cycles until disease progression or unacceptable toxicity or up to a maximum of 63 cycles.
Drug: Azacitidine · Drug: Pevonedistat
Azacitidine intravenous or subcutaneous formulation.
Pevonedistat intravenous infusion.
Event-Free Survival (EFS)
EFS was defined as the time from randomization to the date of an EFS event. An EFS event was defined as death or transformation to acute myelogenous leukemia (AML) (World Health Organization \[WHO\] classification as a participant having greater than 20 % blasts in the blood or marrow and an increase of blast count by 50%), whichever event occurred first, in participants with myelodysplastic syndromes (MDS) or chronic myelomonocytic leukemias (CMML). An EFS event was defined as death in participants with low-blast AML.
Time frame: From randomization until transformation to acute myeloid leukemia, or death due to any cause: up to approximately 42 months
Overall Survival (OS)
Overall survival was defined as the time from randomization to death from any cause.
Time frame: Up to approximately 6.9 years
Kaplan-Meier Estimates of Six-Month Survival Rate
Kaplan-Meier estimates for the probability (expressed as a percentage) of participants that survived at the end of Month 6 from randomization are presented.
Time frame: Month 6
Kaplan-Meier Estimates of One-Year Survival Rate
Kaplan-Meier estimates for the probability (expressed as a percentage) of participants that survived at the end of the first year from randomization are presented.
Time frame: Year 1
Thirty-Day Mortality Reported as Number of Participants Who Died Up to Day 30
30-day mortality was defined as number of participants who died within 30 days from the first dose of study drug.
Time frame: Up to Day 30
Sixty-Day Mortality Reported as Number of Participants Who Died Up to Day 60
60-day mortality was defined as number of participants who died within 60 days from the first dose of study drug.
Time frame: Up to Day 60
Time to Acute Myelogenous Leukemia (AML) Transformation in Higher-Risk Myelodysplastic Syndromes (HR MDS), Higher-Risk Chronic Myelomonocytic Leukemias (HR CMML) and HR MDS/CMML Participants
Time to AML transformation in HR MDS and CMML participants was defined as time from randomization to documented AML transformation as determined by the independent review committee (IRC) assessment. Participants who died before progression to AML were censored. Transformation to AML was defined, according to WHO classification, as a participant having 20% blasts in the blood or marrow and increase of blast count by 50%.
Time frame: From randomization until transformation to AML (up to approximately 42 months)
Number of Participants With Complete Remission (CR) and CR+ Complete Remission With Incomplete Blood Count Recovery (CRi)
CR for HR MDS or CMML is defined as \<=5% myeloblasts with normal maturation of all cell lines in the bone marrow, and greater than or equal to \>=11 gram per deciliter (g/dL) hemoglobin (Hgb),\>=100\*10\^9/liter (/L) platelets (pl),\>=1.0\*10\^9/L neutrophils and 0% blasts in peripheral blood. CR for low-blast AML: morphologic leukemia-free state, neutrophils of more than 1.0\*10\^9/L and pl of \>=100\*10\^9/L, transfusion independence, and no residual evidence of extramedullary leukemia. CR with incomplete blood count recovery (CRi) for low-blast AML: participants fulfill all of the criteria for CR except for residual neutropenia (\<1.0\*10\^9/L) or thrombocytopenia (pl\<100\*10\^9/L).
Time frame: From randomization until CR (up to approximately 42 months)
Number of Participants With CR and Marrow CR
Disease responses for HR MDS or CMML are based on the International Working Group (IWG) Response Criteria for MDS. CR for HR MDS or CMML is defined as \<=5% myeloblasts with normal maturation of all cell lines in the bone marrow, and \>=11 g/dL Hgb, \>=100\*10\^9/L platelets (pl), \>=1.0\*10\^9/L neutrophils and 0% blasts in peripheral blood. Marrow CR: Bone marrow: \<=5% myeloblasts and decrease by \>=50% over pretreatment.
Time frame: From randomization until CR or marrow CR (up to approximately 42 months)
Number of Participants With CR, Partial Remission (PR) and Hematologic Improvement (HI)
Disease responses for HR MDS/CMML based on Modified IWG Response Criteria for MDS. CR: \<=5% myeloblasts with normal maturation of all bone marrow cell lines, \>=11 g/dL Hgb, \>=100\*10\^9/L pl, \>=1.0\*10\^9/L neutrophils,0% blasts in peripheral blood. Marrow CR: Bone marrow: \<=5% myeloblasts and decrease by \>=50% over pretreatment. PR: all CR criteria met except bone marrow blasts \>=50% decrease over pretreatment but still \>5%. HI: Hgb increase \>=1.5 g/dL if \<11 g/dL; pl increase \>=30\*10\^9/L if baseline\>20\*10\^9/L or increase from \<20\*10\^9/L to \>20\*10\^9/L and by at least 100%; neutrophil increase by 100% and absolute increase of \>0.5\*10\^9/L if baseline \<1.0\*10\^9/L.
Time frame: From randomization until, CR, PR or HI (up to approximately 42 months)
Number of Participants With CR and Marrow CR and PR
Disease responses for HR MDS/CMML based on Modified IWG Response Criteria for MDS. CR: \<=5% myeloblasts with normal maturation of all bone marrow cell lines, \>=11 g/dL Hgb, \>=100\*10\^9/L pl, \>=1.0\*10\^9/L neutrophils,0% blasts in peripheral blood. Marrow CR: Bone marrow: \<=5% myeloblasts and decrease by \>=50% over pretreatment. PR: all CR criteria met except bone marrow blasts \>=50% decrease over pretreatment but still \>5%.
Time frame: From randomization until CR or Marrow CR and PR (up to approximately 42 months)
Number of Participants With CR and Marrow CR, PR and Hematologic Improvement (HI)
Disease responses for HR MDS/CMML based on Modified IWG Response Criteria for MDS. CR: \<=5% myeloblasts with normal maturation of all bone marrow cell lines, \>=11 g/dL Hgb, \>=100\*10\^9/L pl, \>=1.0\*10\^9/L neutrophils,0% blasts in peripheral blood. Marrow CR: Bone marrow: \<=5% myeloblasts and decrease by \>=50% over pretreatment. PR: all CR criteria met except bone marrow blasts \>=50% decrease over pretreatment but still\>5%. HI: Hgb increase \>=1.5 g/dL if baseline \<11 g/dL; pl increase \>=30\*10\^9/L if baseline\>20\*10\^9/L or increases from \<20\*10\^9/L to \>20\*10\^9/L and by at least 100%; neutrophil increases by 100% and absolute increases of \>0.5\*10\^9/L if baseline \<1.0\*10\^9/L.
Time frame: From randomization until CR, marrow CR, PR or HI (up to approximately 42 months)
Number of Participants With Overall Response (OR)
Disease responses for HR MDS/CMML based on Modified IWG Response Criteria for MDS; for low-blast AML on Revised IWG Response Criteria for AML. Overall response=CR or PR for HR MDS/CMML and CR + CRi + PR for low-blast AML. CR for HR MDS/CMML: \<=5% myeloblasts with normal maturation of all bone marrow cell lines, \>=11 g/dL Hgb, \>=100\*10\^9/L pl, \>=1.0\*10\^9/L neutrophils, 0% blasts in peripheral blood and PR: all CR criteria met except bone marrow blasts \>=50% decrease over pretreatment but still\>5%. For low-blast AML-CR:morphologic leukemia-free state\>1.0\*10\^9 neutrophils, \>=100\*10\^9/L pl, transfusion independence, no residual evidence of extramedullary leukemia; CR with incomplete blood count recovery (CRi): fulfill CR criteria except residual neutropenia \<1.0\*10\^9/L or pl \<100\*10\^9/L; PR: all CR hematological values but \>=50% decrease in bone marrow aspirate.
Time frame: From randomization until CR and PR or CR, CRi and PR (up to approximately 42 months)
Number of Participants With Overall Response 2 (OR2)
OR2=participant with best overall response of CR+PR+HI in HR MDS/CMML participants,or of CR+CRi+PR in low-blast AML participants.CR:≤5% myeloblasts with normal maturation of all bone marrow(BM)cell lines,≥11g/dL Hgb,≥100\*10\^9/L pl,≥1.0\*10\^9/L neutrophils,0% blasts in peripheral blood;PR:all CR criteria met except BM blasts ≥50% decrease over pretreatment but still \>5%;HI:Hgb increase(inc) ≥1.5g/dL if baseline(BL)\<11 g/dL;pl inc≥30\*10\^9/L if BL\>20\*10\^9/L or inc from \<20\*10\^9/L to \>20\*10\^9/L and by 100%;neutrophil inc by 100%;absolute inc of \>0.5\*10\^9/L if BL\<100\*10\^9/L.For low-blast AML-CR:morphologic leukemia-free state \>1.0\*10\^9 neutrophils,≥100\*10\^9/L pl,transfusion independence,no residual evidence of extramedullary leukemia;CR with incomplete blood count recovery:fulfill CR criteria except residual neutropenia \<1.0\*10\^9/L or pl\<100\*10\^9/L;PR:all CR hematological values but ≥50% decrease in BM aspirate.Number of responders determined by independent review committee(IRC) assessment.
Time frame: From randomization until, CR, PR or HI or CR, CRi or PR (up to approximately 42 months)
Duration of Complete Remission (CR)
Duration of CR is first documented CR to the first documentation of PD or relapse from CR (participants with low-blast AML) or relapse after CR or PR (participants with HR MDS/CMML). Disease responses for HR MDS or CMML are based on the Modified IWG Response Criteria for MDS and for low-blast AML on the Revised IWG Response Criteria for AML. CR for HR MDS or CMML is defined as \<=5% myeloblasts with normal maturation of all cell lines in the bone marrow, and greater than or equal to \>=11 g/dL Hgb,\>=100\*10\^9/L pl,\>=1.0\*10\^9/L neutrophils and 0% blasts in peripheral blood. CR for low-blast AML: morphologic leukemia-free state, neutrophils of more than 1.0\*10\^9/L and pl of \>=100\*10\^9/L, transfusion independence, and no residual evidence of extramedullary leukemia. CR with incomplete blood count recovery (CRi) for low-blast AML: participants fulfill all of the criteria for CR except for residual neutropenia (\<1.0\*10\^9/L) or thrombocytopenia (pl\<100\*10\^9/L).
Time frame: From CR until first documentation of PD or relapse from CR or relapse after CR or PR (up to approximately 42 months)
Duration of Complete Remission + Complete Remission With Incomplete Blood Count Recovery (CRi)
Duration of CR is first documented CR to the first documentation of PD or relapse from CR (participants with low-blast AML). Disease responses for low-blast AML were based on the Revised IWG Response Criteria for AML. CR is defined as \<=5% myeloblasts with normal maturation of all cell lines in the bone marrow, and greater than or equal to \>=11 g/dL hemoglobin (Hgb),\>=100\*10\^9/liter (/L) platelets (pl),\>=1.0\*10\^9/L neutrophils and 0% blasts in peripheral blood. CR for low-blast AML: morphologic leukemia-free state, neutrophils of more than 1.0\*10\^9/L and pl of \>=100\*10\^9/L, transfusion independence, and no residual evidence of extramedullary leukemia. CR with incomplete blood count recovery (CRi) for low-blast AML: participants fulfill all of the criteria for CR except for residual neutropenia (\<1.0\*10\^9/L) or thrombocytopenia (pl\<100\*10\^9/L).
Time frame: From CR until first documentation of PD or relapse from CR or relapse after CR or PR (up to approximately 42 months)
Duration of Overall Response (OR)
Duration of OR: response to first documentation of PD or relapse from CR for low-blast AML or relapse after CR or PR for HR MDS/CMML. Disease responses for HR MDS/CMML based on Modified IWG Response Criteria for MDS; for low-blast AML on Revised IWG Response Criteria for AML. Overall response=CR+PR for HR MDS/CMML and CR+Cri+ PR for low-blast AML.CR for HR MDS/CMML:\<=5% myeloblasts with normal maturation of all bone marrow cell lines,\>=11 g/dL Hgb,\>=100\*10\^9/L pl,\>=1.0\*10\^9/L neutrophils,0% blasts in peripheral blood and PR:all CR criteria met except bone marrow blasts\>=50% decrease over pretreatment but still \>5%. For low-blast AML-CR: morphologic leukemia-free state \>1.0\*10\^9 neutrophils,\>=100\*10\^9/L pl, transfusion independence, no residual evidence of extramedullary leukemia; CR with CRi: fulfill CR criteria except residual neutropenia \<1.0\*10\^9/L or pl \<100\*10\^9/L; PR: all CR hematological values but \>=50% decrease in % of blasts in bone marrow aspirate.
Time frame: Up to approximately 42 months
Duration of Overall Response 2 (OR2)
Duration of OR2: from date of first documentation of CR+PR+HI to first documentation of PD/relapse after CR/PR for responders of CR+PR+HI for HR MDS/CMML and CR,CRi,PR for low-blast AML. For HR MDS/CMML-CR:\<=5% myeloblasts with normal maturation of all bone marrow cell lines,\>=11 g/dL Hgb, \>=100\*10\^9/L pl,\>=1.0\*10\^9/L neutrophils, 0% blasts in peripheral blood; PR: all CR criteria met except bone marrow blasts\>=50% decrease over pretreatment, still \>5%; HI:Hgb inc \>=1.5 g/dL if baseline \<11 g/dL; pl inc\>=30\*10\^9/L if baseline\>20\*10\^9/L or inc from\<20\*10\^9/L to\>20\*10\^9/L by at least 100%; neutrophil inc by 100% and absolute inc of \>0.5\*10\^9/L if baseline \<1.0\*10\^9/L.For low-blast AML-CR: morphologic leukemia-free state,\>1.0\*10\^9 neutrophils,\>=100\*10\^9/L pl, transfusion independence, no residual evidence of extramedullary leukemia;CRi: fulfill CR criteria except residual neutropenia\<1.0\*10\^9/L or pl \<100\*10\^9/L;PR:all CR hematological values but\>=50% decrease in bone marrow aspirate.
Time frame: Up to approximately 42 months
Percentage of Participants With Red Blood Cells (RBCs) and Platelet-transfusion Independence
A participant was defined as RBC or platelet-transfusion independent if he/she received no RBC or platelet transfusions for a period of at least 8 weeks before the first dose of study drug through 30 days after the last dose of any study drug. Rate of transfusion independence was defined as number of participants who became transfusion independent divided by the number of participants who were transfusion dependent at Baseline.
Time frame: Up to approximately 42 months
Duration of Red Blood Cells (RBCs) and Duration of Platelet-transfusion Independence and Duration of Red Blood Cells (RBCs) and Platelet-transfusion Independence
Duration of RBC and platelet transfusion independence was defined as the longest time between the last RBC and/or platelet transfusion before the start of the RBC and/or platelet transfusion-independent period and the first RBC and/or platelet transfusion after the start of the transfusion-independent period, which occurs \>= 8 weeks later.
Time frame: Up to approximately 42 months
Time to First Complete Remission (CR) or Partial Remission (PR) or Complete Remission With Incomplete Blood Count Recovery (CRi)
Time to first CR or PR is defined as the time from randomization to first documented CR or PR, whichever occurs first. Disease responses for HR MDS or CMML or low-blast AML cycle 6 are based on Modified IWG Response Criteria for MDS and for low-blast AML on Revised IWG Response Criteria for AML. For HR MDS or CMML-CR:\<=5% myeloblasts with normal maturation of all bone marrow cell lines,\>=11 g/dL Hgb,\>=100\*10\^9/L pl,\>=1.0\*10\^9/L neutrophils, 0% blasts in peripheral blood; PR: all CR criteria met except bone marrow blasts\>=50% decrease over pretreatment but still\>5%; For low-blast AML-CR: morphologic leukemia-free state,\>1.0\*10\^9/L neutrophils, pl\>=100\*10\^9/L, transfusion independence, no residual evidence of extramedullary leukemia; CR with incomplete blood count recovery: fulfill CR criteria except residual neutropenia\<1.0\*10\^9/L or pl \<100\*10\^9/L; PR: all CR hematological values but with a decrease of at least 50% in the percentage of blasts to 5% to 25% in the bone marrow aspirate.
Time frame: From randomization until CR or PR (up to approximately 42 months)
Number of Participants With Hematologic Improvement (HI)
Disease responses for HR MDS/CMML based on Modified IWG Response Criteria for MDS. HI: Hgb increase \>=1.5 g/dL if baseline \<11 g/dL; pl increase \>=30\*10\^9/L if baseline \>20\*10\^9/L or increase from \<20\*10\^9/L to \>20\*10\^9/L by at least 100%; neutrophil increase by 100% and absolute increase of \>0.5\*10\^9/L if baseline \<1.0\*10\^9/L.
Time frame: From randomization until HI (up to approximately 42 months)
Number of Participants With at Least 1 Inpatient Hospital Admissions Related to HR MDS, CMML or Low-blast AML
Inpatient hospital admission data was collected through transformation to AML (HR MDS/CMML participants) or disease progression (low-blast AML participants) or until initiation of subsequent therapy (all participants), whichever occurred first. Transformation to AML is defined, according to WHO Classification, as a participant having 20% blasts in the blood or marrow and increase of blast count by 50%.
Time frame: From randomization until transformation to AML or until initiation of subsequent therapy (up to approximately 42 months)
Time to Progressive Disease (PD), Relapse After CR (Low-blast AML), Relapse After CR or PR (HR MDS/CMML), or Death
Time to PD, relapse after CR(low-blast AML), relapse after CR or PR(HR MDS/CMML), or death,defined as time from date of randomization until date of first documentation of PD,relapse after CR(low-blast AML),relapse after CR or PR(HR MDS/CMML),or death due to any cause, whichever occurs first. In HR MDS/CMML,PD: Participants with\<5% blasts:\>=50% inc \>5% blasts, with 5%-9% blasts:\>=50% inc\>10% blasts, with 10%-19% blasts:\>=50% inc \>20% blasts,with 20%-30% blasts, at least 50% decrement from maximum remission/response in granulocytes or pl or reduction in Hgb by\>=2 g/dL/new transfusion dependence.Relapse after CR or PR: return to pretreatment bone marrow blast %/Decrement of \>=50% from maximum remission/response levels in granulocytes/pl/reduction in Hgb conc.\>=1.5 g/dL/transfusion dependence. In AML,PD:\>50% inc in bone marrow blasts to \>30% blasts,\>50% inc in circulating blasts to\>30% blasts in peripheral blood, Development of extramedullary disease/new sites of extramedullary leukemia.
Time frame: From randomization until PD, relapse after CR, or relapse after CR or PR, or death due to any cause, whichever occurs first (up to approximately 42 months)
Change From Baseline in Health-Related Quality of Life (HRQOL) Using European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire- Core 30
The EORTC QLQ-C30 contains 30 items across 5 functional scales (physical, role, cognitive, emotional, and social), 9 symptom scales (fatigue, nausea and vomiting, pain, dyspnea, sleep disturbance, appetite loss, constipation, diarrhea, and financial difficulties) and a global health status/QOL scale. Most of the 30 items have 4 response levels (not at all, a little, quite a bit, and very much), with 2 questions relying on a 7-point numeric rating scale. Raw scores are converted into scale scores ranging from 0 to 100. For the functional scales and the global health status/QOL scale, higher scores represent better QOL; for the symptom scales, lower scores represent better QOL. The change from baseline at end of treatment is reported.
Time frame: Baseline, at approximately 58 months
Number of Participants With Overall Response in Participants Who Have TP53 Mutations, 17p Deletions, and/or Are Determined to be in an Adverse Cytogenetic Risk Group
Disease responses for HR MDS/CMML based on Modified IWG Response Criteria for MDS; for low-blast AML on Revised IWG Response Criteria for AML. Overall response=CR + PR for HR MDS/CMML and CR + CRi + PR for low-blast AML. CR for HR MDS/CMML: \<=5% myeloblasts with normal maturation of all bone marrow cell lines, \>=11 g/dL Hgb, \>=100\*10\^9/L pl, \>=1.0\*10\^9/L neutrophils,0% blasts in peripheral blood and PR: all CR criteria met except bone marrow blasts\>=50% decrease over pretreatment but still\>5%. For low-blast AML-CR: morphologic leukemia-free state, \>1.0\*10\^9 neutrophils,\>=100\*10\^9/L pl, transfusion independence, no residual evidence of extramedullary leukemia; CR with incomplete blood count recovery (CRi): fulfill CR criteria except residual neutropenia\<1.0\*10\^9/L or pl\<100\*10\^9/L; PR: all CR hematological values but\>=50% decrease in the percentage of blasts to 5% to 25% in bone marrow aspirate.
Time frame: From randomization until CR, CRi and PR (up to approximately 42 months)
Event-Free Survival in Participants Who Have TP53 Mutations, 17p Deletions, and/or Are Determined to be in an Adverse Cytogenetic Risk Group
Event was defined as death or transformation to AML in participants with MDS or CMML, whichever occurred first. Transformation to AML was defined, according to World Health Organization (WHO) Classification as a participant having \>20% blasts in the blood or marrow and increase of blast count by 50%. Event was defined as death in participants with low-blast AML.
Time frame: From randomization until transformation to AML if eligible or death (up to approximately 42 months)
Overall Survival in Participants Who Have TP53 Mutations, 17p Deletions, and/or Are Determined to be in an Adverse Cytogenetic Risk Group
OS was calculated from date of randomization to the date of death due to any cause. Participants without documented death at the time of the analysis were censored as of the date the participant was last known to be alive.
Time frame: From randomization until death (up to approximately 42 months)
Number of Participants With Overall Response by Cycle 6
Responses for HR MDS/CMML are based on Modified International Working Group (IWG) Response Criteria for MDS and for low-blast AML on Revised IWG Response Criteria for AML. Overall response=CR and PR for HR MDS/CMML and CR+CR with incomplete blood count recovery(CRi)+PR for low-blast AML. CR for HR MDS/CMML:\<=5% myeloblasts with normal maturation of all bone marrow cell lines,\>=11g/dL hemoglobin (Hgb),\>=100\*10\^9/L platelet (pl),\>=1.0\*10\^9/L neutrophils, 0% blasts in peripheral blood, and PR:all CR criteria met except bone marrow blasts \>=50% decrease over pretreatment but still \>5%. For low-blast AML-CR:morphologic leukemia-free state,\>1.0\*10\^9 neutrophils, \>=100\*10\^9/L pl, transfusion independence, no residual evidence of extramedullary leukemia;CRi:fulfill CR criteria except residual neutropenia \<1.0\*10\^9/L/thrombocytopenia (pl\<100\*10\^9/L); PR:all CR hematological values but\>=50% decrease in percentage of blasts to 5%-25% in bone marrow aspirate.
Time frame: Up to Cycle 6 (up to approximately Day 168)
Participants took part in the study at 130 investigative sites globally from 28 November 2017 to 14 October 2024.
| Milestone | Azacitidine 75 mg/m^2 | Pevonedistat 20 mg/m^2 + Azacitidine 75 mg/m^2 |
|---|---|---|
| Started | 227 | 227 |
| Safety population | 220 | 223 |
| Completed | 195 | 199 |
| Not completed | 32 | 28 |
| Withdrew: Withdrawal by subject | 27 | 17 |
| Withdrew: Lost to follow-up | 2 | 3 |
| Withdrew: Reason not specified | 3 | 8 |
EFS was defined as the time from randomization to the date of an EFS event. An EFS event was defined as death or transformation to acute myelogenous leukemia (AML) (World Health Organization \[WHO\] classification as a participant having greater than 20 % blasts in the blood or marrow and an increase of blast count by 50%), whichever event occurred first, in participants with myelodysplastic syndromes (MDS) or chronic myelomonocytic leukemias (CMML). An EFS event was defined as death in participants with low-blast AML.
| months | Azacitidine 75 mg/m^2 | Pevonedistat 20 mg/m^2 + Azacitidine 75 mg/m^2 |
|---|---|---|
| Event-Free Survival (EFS) | 15.7 (14.42 to 19.68) | 17.7 (13.63 to 20.24) |
Overall survival was defined as the time from randomization to death from any cause.
| months | Azacitidine 75 mg/m^2 | Pevonedistat 20 mg/m^2 + Azacitidine 75 mg/m^2 |
|---|---|---|
| Overall Survival (OS) | 16.8 (14.92 to 20.11) | 20.3 (17.97 to 22.60) |
Kaplan-Meier estimates for the probability (expressed as a percentage) of participants that survived at the end of Month 6 from randomization are presented.
| percentage probability | Azacitidine 75 mg/m^2 | Pevonedistat 20 mg/m^2 + Azacitidine 75 mg/m^2 |
|---|---|---|
| Kaplan-Meier Estimates of Six-Month Survival Rate | 0.825 (0.767 to 0.869) | 0.810 (0.752 to 0.856) |
Kaplan-Meier estimates for the probability (expressed as a percentage) of participants that survived at the end of the first year from randomization are presented.
| percentage probability | Azacitidine 75 mg/m^2 | Pevonedistat 20 mg/m^2 + Azacitidine 75 mg/m^2 |
|---|---|---|
| Kaplan-Meier Estimates of One-Year Survival Rate | 0.693 (0.626 to 0.751) | 0.646 (0.578 to 0.706) |
30-day mortality was defined as number of participants who died within 30 days from the first dose of study drug.
| Participants | Azacitidine 75 mg/m^2 | Pevonedistat 20 mg/m^2 + Azacitidine 75 mg/m^2 |
|---|---|---|
| Thirty-Day Mortality Reported as Number of Participants Who Died Up to Day 30 | 6 | 5 |
60-day mortality was defined as number of participants who died within 60 days from the first dose of study drug.
| Participants | Azacitidine 75 mg/m^2 | Pevonedistat 20 mg/m^2 + Azacitidine 75 mg/m^2 |
|---|---|---|
| Sixty-Day Mortality Reported as Number of Participants Who Died Up to Day 60 | 15 | 14 |
Time to AML transformation in HR MDS and CMML participants was defined as time from randomization to documented AML transformation as determined by the independent review committee (IRC) assessment. Participants who died before progression to AML were censored. Transformation to AML was defined, according to WHO classification, as a participant having 20% blasts in the blood or marrow and increase of blast count by 50%.
| months | Azacitidine 75 mg/m^2 | Pevonedistat 20 mg/m^2 + Azacitidine 75 mg/m^2 |
|---|---|---|
| HR MDS Participants | 35.6 (26.51 to NA) | NA (23.29 to NA) |
| HR CMML Participants | NA (NA to NA) | NA (NA to NA) |
| HR MDS/CMML Participants | 35.6 (29.04 to NA) | NA (24.28 to NA) |
CR for HR MDS or CMML is defined as \<=5% myeloblasts with normal maturation of all cell lines in the bone marrow, and greater than or equal to \>=11 gram per deciliter (g/dL) hemoglobin (Hgb),\>=100\*10\^9/liter (/L) platelets (pl),\>=1.0\*10\^9/L neutrophils and 0% blasts in peripheral blood. CR for low-blast AML: morphologic leukemia-free state, neutrophils of more than 1.0\*10\^9/L and pl of \>=100\*10\^9/L, transfusion independence, and no residual evidence of extramedullary leukemia. CR with incomplete blood count recovery (CRi) for low-blast AML: participants fulfill all of the criteria for CR except for residual neutropenia (\<1.0\*10\^9/L) or thrombocytopenia (pl\<100\*10\^9/L).
| Participants | Azacitidine 75 mg/m^2 | Pevonedistat 20 mg/m^2 + Azacitidine 75 mg/m^2 |
|---|---|---|
| Number of Participants With Complete Remission (CR) and CR+ Complete Remission With Incomplete Blood Count Recovery (CRi) | 71 | 63 |
Disease responses for HR MDS or CMML are based on the International Working Group (IWG) Response Criteria for MDS. CR for HR MDS or CMML is defined as \<=5% myeloblasts with normal maturation of all cell lines in the bone marrow, and \>=11 g/dL Hgb, \>=100\*10\^9/L platelets (pl), \>=1.0\*10\^9/L neutrophils and 0% blasts in peripheral blood. Marrow CR: Bone marrow: \<=5% myeloblasts and decrease by \>=50% over pretreatment.
| Participants | Azacitidine 75 mg/m^2 | Pevonedistat 20 mg/m^2 + Azacitidine 75 mg/m^2 |
|---|---|---|
| Number of Participants With CR and Marrow CR | 91 | 87 |
Disease responses for HR MDS/CMML based on Modified IWG Response Criteria for MDS. CR: \<=5% myeloblasts with normal maturation of all bone marrow cell lines, \>=11 g/dL Hgb, \>=100\*10\^9/L pl, \>=1.0\*10\^9/L neutrophils,0% blasts in peripheral blood. Marrow CR: Bone marrow: \<=5% myeloblasts and decrease by \>=50% over pretreatment. PR: all CR criteria met except bone marrow blasts \>=50% decrease over pretreatment but still \>5%. HI: Hgb increase \>=1.5 g/dL if \<11 g/dL; pl increase \>=30\*10\^9/L if baseline\>20\*10\^9/L or increase from \<20\*10\^9/L to \>20\*10\^9/L and by at least 100%; neutrophil increase by 100% and absolute increase of \>0.5\*10\^9/L if baseline \<1.0\*10\^9/L.
| Participants | Azacitidine 75 mg/m^2 | Pevonedistat 20 mg/m^2 + Azacitidine 75 mg/m^2 |
|---|---|---|
| Number of Participants With CR, Partial Remission (PR) and Hematologic Improvement (HI) | 77 | 76 |
Disease responses for HR MDS/CMML based on Modified IWG Response Criteria for MDS. CR: \<=5% myeloblasts with normal maturation of all bone marrow cell lines, \>=11 g/dL Hgb, \>=100\*10\^9/L pl, \>=1.0\*10\^9/L neutrophils,0% blasts in peripheral blood. Marrow CR: Bone marrow: \<=5% myeloblasts and decrease by \>=50% over pretreatment. PR: all CR criteria met except bone marrow blasts \>=50% decrease over pretreatment but still \>5%.
| Participants | Azacitidine 75 mg/m^2 | Pevonedistat 20 mg/m^2 + Azacitidine 75 mg/m^2 |
|---|---|---|
| Number of Participants With CR and Marrow CR and PR | 91 | 87 |
Disease responses for HR MDS/CMML based on Modified IWG Response Criteria for MDS. CR: \<=5% myeloblasts with normal maturation of all bone marrow cell lines, \>=11 g/dL Hgb, \>=100\*10\^9/L pl, \>=1.0\*10\^9/L neutrophils,0% blasts in peripheral blood. Marrow CR: Bone marrow: \<=5% myeloblasts and decrease by \>=50% over pretreatment. PR: all CR criteria met except bone marrow blasts \>=50% decrease over pretreatment but still\>5%. HI: Hgb increase \>=1.5 g/dL if baseline \<11 g/dL; pl increase \>=30\*10\^9/L if baseline\>20\*10\^9/L or increases from \<20\*10\^9/L to \>20\*10\^9/L and by at least 100%; neutrophil increases by 100% and absolute increases of \>0.5\*10\^9/L if baseline \<1.0\*10\^9/L.
| Participants | Azacitidine 75 mg/m^2 | Pevonedistat 20 mg/m^2 + Azacitidine 75 mg/m^2 |
|---|---|---|
| Number of Participants With CR and Marrow CR, PR and Hematologic Improvement (HI) | 112 | 117 |
Disease responses for HR MDS/CMML based on Modified IWG Response Criteria for MDS; for low-blast AML on Revised IWG Response Criteria for AML. Overall response=CR or PR for HR MDS/CMML and CR + CRi + PR for low-blast AML. CR for HR MDS/CMML: \<=5% myeloblasts with normal maturation of all bone marrow cell lines, \>=11 g/dL Hgb, \>=100\*10\^9/L pl, \>=1.0\*10\^9/L neutrophils, 0% blasts in peripheral blood and PR: all CR criteria met except bone marrow blasts \>=50% decrease over pretreatment but still\>5%. For low-blast AML-CR:morphologic leukemia-free state\>1.0\*10\^9 neutrophils, \>=100\*10\^9/L pl, transfusion independence, no residual evidence of extramedullary leukemia; CR with incomplete blood count recovery (CRi): fulfill CR criteria except residual neutropenia \<1.0\*10\^9/L or pl \<100\*10\^9/L; PR: all CR hematological values but \>=50% decrease in bone marrow aspirate.
| Participants | Azacitidine 75 mg/m^2 | Pevonedistat 20 mg/m^2 + Azacitidine 75 mg/m^2 |
|---|---|---|
| Number of Participants With Overall Response (OR) | 73 | 64 |
OR2=participant with best overall response of CR+PR+HI in HR MDS/CMML participants,or of CR+CRi+PR in low-blast AML participants.CR:≤5% myeloblasts with normal maturation of all bone marrow(BM)cell lines,≥11g/dL Hgb,≥100\*10\^9/L pl,≥1.0\*10\^9/L neutrophils,0% blasts in peripheral blood;PR:all CR criteria met except BM blasts ≥50% decrease over pretreatment but still \>5%;HI:Hgb increase(inc) ≥1.5g/dL if baseline(BL)\<11 g/dL;pl inc≥30\*10\^9/L if BL\>20\*10\^9/L or inc from \<20\*10\^9/L to \>20\*10\^9/L and by 100%;neutrophil inc by 100%;absolute inc of \>0.5\*10\^9/L if BL\<100\*10\^9/L.For low-blast AML-CR:morphologic leukemia-free state \>1.0\*10\^9 neutrophils,≥100\*10\^9/L pl,transfusion independence,no residual evidence of extramedullary leukemia;CR with incomplete blood count recovery:fulfill CR criteria except residual neutropenia \<1.0\*10\^9/L or pl\<100\*10\^9/L;PR:all CR hematological values but ≥50% decrease in BM aspirate.Number of responders determined by independent review committee(IRC) assessment.
| Participants | Azacitidine 75 mg/m^2 | Pevonedistat 20 mg/m^2 + Azacitidine 75 mg/m^2 |
|---|---|---|
| Number of Participants With Overall Response 2 (OR2) | 94 | 94 |
Duration of CR is first documented CR to the first documentation of PD or relapse from CR (participants with low-blast AML) or relapse after CR or PR (participants with HR MDS/CMML). Disease responses for HR MDS or CMML are based on the Modified IWG Response Criteria for MDS and for low-blast AML on the Revised IWG Response Criteria for AML. CR for HR MDS or CMML is defined as \<=5% myeloblasts with normal maturation of all cell lines in the bone marrow, and greater than or equal to \>=11 g/dL Hgb,\>=100\*10\^9/L pl,\>=1.0\*10\^9/L neutrophils and 0% blasts in peripheral blood. CR for low-blast AML: morphologic leukemia-free state, neutrophils of more than 1.0\*10\^9/L and pl of \>=100\*10\^9/L, transfusion independence, and no residual evidence of extramedullary leukemia. CR with incomplete blood count recovery (CRi) for low-blast AML: participants fulfill all of the criteria for CR except for residual neutropenia (\<1.0\*10\^9/L) or thrombocytopenia (pl\<100\*10\^9/L).
| months | Azacitidine 75 mg/m^2 | Pevonedistat 20 mg/m^2 + Azacitidine 75 mg/m^2 |
|---|---|---|
| Duration of Complete Remission (CR) | 13.1 (6.93 to 29.08) | 17.2 (13.96 to NA) |
Duration of CR is first documented CR to the first documentation of PD or relapse from CR (participants with low-blast AML). Disease responses for low-blast AML were based on the Revised IWG Response Criteria for AML. CR is defined as \<=5% myeloblasts with normal maturation of all cell lines in the bone marrow, and greater than or equal to \>=11 g/dL hemoglobin (Hgb),\>=100\*10\^9/liter (/L) platelets (pl),\>=1.0\*10\^9/L neutrophils and 0% blasts in peripheral blood. CR for low-blast AML: morphologic leukemia-free state, neutrophils of more than 1.0\*10\^9/L and pl of \>=100\*10\^9/L, transfusion independence, and no residual evidence of extramedullary leukemia. CR with incomplete blood count recovery (CRi) for low-blast AML: participants fulfill all of the criteria for CR except for residual neutropenia (\<1.0\*10\^9/L) or thrombocytopenia (pl\<100\*10\^9/L).
| months | Azacitidine 75 mg/m^2 | Pevonedistat 20 mg/m^2 + Azacitidine 75 mg/m^2 |
|---|---|---|
| Duration of Complete Remission + Complete Remission With Incomplete Blood Count Recovery (CRi) | 8.5 (3.02 to NA) | 15.0 (3.94 to NA) |
Duration of OR: response to first documentation of PD or relapse from CR for low-blast AML or relapse after CR or PR for HR MDS/CMML. Disease responses for HR MDS/CMML based on Modified IWG Response Criteria for MDS; for low-blast AML on Revised IWG Response Criteria for AML. Overall response=CR+PR for HR MDS/CMML and CR+Cri+ PR for low-blast AML.CR for HR MDS/CMML:\<=5% myeloblasts with normal maturation of all bone marrow cell lines,\>=11 g/dL Hgb,\>=100\*10\^9/L pl,\>=1.0\*10\^9/L neutrophils,0% blasts in peripheral blood and PR:all CR criteria met except bone marrow blasts\>=50% decrease over pretreatment but still \>5%. For low-blast AML-CR: morphologic leukemia-free state \>1.0\*10\^9 neutrophils,\>=100\*10\^9/L pl, transfusion independence, no residual evidence of extramedullary leukemia; CR with CRi: fulfill CR criteria except residual neutropenia \<1.0\*10\^9/L or pl \<100\*10\^9/L; PR: all CR hematological values but \>=50% decrease in % of blasts in bone marrow aspirate.
| months | Azacitidine 75 mg/m^2 | Pevonedistat 20 mg/m^2 + Azacitidine 75 mg/m^2 |
|---|---|---|
| Duration of Overall Response (OR) | 18.3 (8.31 to NA) | 17.1 (12.68 to NA) |
Duration of OR2: from date of first documentation of CR+PR+HI to first documentation of PD/relapse after CR/PR for responders of CR+PR+HI for HR MDS/CMML and CR,CRi,PR for low-blast AML. For HR MDS/CMML-CR:\<=5% myeloblasts with normal maturation of all bone marrow cell lines,\>=11 g/dL Hgb, \>=100\*10\^9/L pl,\>=1.0\*10\^9/L neutrophils, 0% blasts in peripheral blood; PR: all CR criteria met except bone marrow blasts\>=50% decrease over pretreatment, still \>5%; HI:Hgb inc \>=1.5 g/dL if baseline \<11 g/dL; pl inc\>=30\*10\^9/L if baseline\>20\*10\^9/L or inc from\<20\*10\^9/L to\>20\*10\^9/L by at least 100%; neutrophil inc by 100% and absolute inc of \>0.5\*10\^9/L if baseline \<1.0\*10\^9/L.For low-blast AML-CR: morphologic leukemia-free state,\>1.0\*10\^9 neutrophils,\>=100\*10\^9/L pl, transfusion independence, no residual evidence of extramedullary leukemia;CRi: fulfill CR criteria except residual neutropenia\<1.0\*10\^9/L or pl \<100\*10\^9/L;PR:all CR hematological values but\>=50% decrease in bone marrow aspirate.
| months | Azacitidine 75 mg/m^2 | Pevonedistat 20 mg/m^2 + Azacitidine 75 mg/m^2 |
|---|---|---|
| Duration of Overall Response 2 (OR2) | 18.3 (11.17 to 30.92) | 18.9 (15.01 to NA) |
A participant was defined as RBC or platelet-transfusion independent if he/she received no RBC or platelet transfusions for a period of at least 8 weeks before the first dose of study drug through 30 days after the last dose of any study drug. Rate of transfusion independence was defined as number of participants who became transfusion independent divided by the number of participants who were transfusion dependent at Baseline.
| percentage of participants | Azacitidine 75 mg/m^2 | Pevonedistat 20 mg/m^2 + Azacitidine 75 mg/m^2 |
|---|---|---|
| Percentage of Participants With RBCs-transfusion Independence | 44.3 | 47.5 |
| Percentage of Participants With Platelet-transfusion Independence | 48.9 | 45.5 |
Duration of RBC and platelet transfusion independence was defined as the longest time between the last RBC and/or platelet transfusion before the start of the RBC and/or platelet transfusion-independent period and the first RBC and/or platelet transfusion after the start of the transfusion-independent period, which occurs \>= 8 weeks later.
| months | Azacitidine 75 mg/m^2 | Pevonedistat 20 mg/m^2 + Azacitidine 75 mg/m^2 |
|---|---|---|
| Duration of RBC Transfusion Independence | 15.6 (10.18 to 28.09) | 13.5 (9.07 to 16.66) |
| Duration of Platelet Transfusion Independence | 14.9 (5.09 to 23.23) | 11.6 (2.73 to 16.26) |
| Duration of Transfusion Independence | 12.0 (8.90 to 19.48) | 13.5 (10.38 to 16.66) |
Time to first CR or PR is defined as the time from randomization to first documented CR or PR, whichever occurs first. Disease responses for HR MDS or CMML or low-blast AML cycle 6 are based on Modified IWG Response Criteria for MDS and for low-blast AML on Revised IWG Response Criteria for AML. For HR MDS or CMML-CR:\<=5% myeloblasts with normal maturation of all bone marrow cell lines,\>=11 g/dL Hgb,\>=100\*10\^9/L pl,\>=1.0\*10\^9/L neutrophils, 0% blasts in peripheral blood; PR: all CR criteria met except bone marrow blasts\>=50% decrease over pretreatment but still\>5%; For low-blast AML-CR: morphologic leukemia-free state,\>1.0\*10\^9/L neutrophils, pl\>=100\*10\^9/L, transfusion independence, no residual evidence of extramedullary leukemia; CR with incomplete blood count recovery: fulfill CR criteria except residual neutropenia\<1.0\*10\^9/L or pl \<100\*10\^9/L; PR: all CR hematological values but with a decrease of at least 50% in the percentage of blasts to 5% to 25% in the bone marrow aspirate.
| months | Azacitidine 75 mg/m^2 | Pevonedistat 20 mg/m^2 + Azacitidine 75 mg/m^2 |
|---|---|---|
| Time to First Complete Remission (CR) or Partial Remission (PR) or Complete Remission With Incomplete Blood Count Recovery (CRi) | NA (12.12 to NA) | NA (24.61 to NA) |
Disease responses for HR MDS/CMML based on Modified IWG Response Criteria for MDS. HI: Hgb increase \>=1.5 g/dL if baseline \<11 g/dL; pl increase \>=30\*10\^9/L if baseline \>20\*10\^9/L or increase from \<20\*10\^9/L to \>20\*10\^9/L by at least 100%; neutrophil increase by 100% and absolute increase of \>0.5\*10\^9/L if baseline \<1.0\*10\^9/L.
| Participants | Azacitidine 75 mg/m^2 | Pevonedistat 20 mg/m^2 + Azacitidine 75 mg/m^2 |
|---|---|---|
| Number of Participants With Hematologic Improvement (HI) | 76 | 70 |
Inpatient hospital admission data was collected through transformation to AML (HR MDS/CMML participants) or disease progression (low-blast AML participants) or until initiation of subsequent therapy (all participants), whichever occurred first. Transformation to AML is defined, according to WHO Classification, as a participant having 20% blasts in the blood or marrow and increase of blast count by 50%.
| Participants | Azacitidine 75 mg/m^2 | Pevonedistat 20 mg/m^2 + Azacitidine 75 mg/m^2 |
|---|---|---|
| Number of Participants With at Least 1 Inpatient Hospital Admissions Related to HR MDS, CMML or Low-blast AML | 3 | 9 |
Time to PD, relapse after CR(low-blast AML), relapse after CR or PR(HR MDS/CMML), or death,defined as time from date of randomization until date of first documentation of PD,relapse after CR(low-blast AML),relapse after CR or PR(HR MDS/CMML),or death due to any cause, whichever occurs first. In HR MDS/CMML,PD: Participants with\<5% blasts:\>=50% inc \>5% blasts, with 5%-9% blasts:\>=50% inc\>10% blasts, with 10%-19% blasts:\>=50% inc \>20% blasts,with 20%-30% blasts, at least 50% decrement from maximum remission/response in granulocytes or pl or reduction in Hgb by\>=2 g/dL/new transfusion dependence.Relapse after CR or PR: return to pretreatment bone marrow blast %/Decrement of \>=50% from maximum remission/response levels in granulocytes/pl/reduction in Hgb conc.\>=1.5 g/dL/transfusion dependence. In AML,PD:\>50% inc in bone marrow blasts to \>30% blasts,\>50% inc in circulating blasts to\>30% blasts in peripheral blood, Development of extramedullary disease/new sites of extramedullary leukemia.
| months | Azacitidine 75 mg/m^2 | Pevonedistat 20 mg/m^2 + Azacitidine 75 mg/m^2 |
|---|---|---|
| Time to Progressive Disease (PD), Relapse After CR (Low-blast AML), Relapse After CR or PR (HR MDS/CMML), or Death | 11.8 (10.25 to 13.31) | 13.1 (11.01 to 15.84) |
The EORTC QLQ-C30 contains 30 items across 5 functional scales (physical, role, cognitive, emotional, and social), 9 symptom scales (fatigue, nausea and vomiting, pain, dyspnea, sleep disturbance, appetite loss, constipation, diarrhea, and financial difficulties) and a global health status/QOL scale. Most of the 30 items have 4 response levels (not at all, a little, quite a bit, and very much), with 2 questions relying on a 7-point numeric rating scale. Raw scores are converted into scale scores ranging from 0 to 100. For the functional scales and the global health status/QOL scale, higher scores represent better QOL; for the symptom scales, lower scores represent better QOL. The change from baseline at end of treatment is reported.
| score on a scale | Azacitidine 75 mg/m^2 | Pevonedistat 20 mg/m^2 + Azacitidine 75 mg/m^2 |
|---|---|---|
| Global Health Status/QoL Score: Baseline | 60.3 ± 22.11 | 61.6 ± 21.13 |
| Global Health Status/QoL Score: Change from Baseline | -3.0 ± 25.93 | -8.4 ± 26.89 |
| Physical Functioning Score: Baseline | 69.4 ± 22.63 | 75.7 ± 20.38 |
| Physical Functioning Score: Change from Baseline | -7.5 ± 22.82 | -13.4 ± 27.51 |
| Role Functioning Score: Baseline | 66.9 ± 30.88 | 73.7 ± 28.55 |
| Role Functioning Score: Change from Baseline | -11.8 ± 35.41 | -18.3 ± 36.72 |
| Emotional Functioning Score: Baseline | 76.0 ± 20.96 | 77.6 ± 22.10 |
| Emotional Functioning Score: Change from Baselline | -2.5 ± 23.80 | -5.9 ± 22.41 |
| Cognitive Functioning Score: Baseline | 84.6 ± 18.29 | 86.1 ± 17.60 |
| Cognitive Functioning Score: Change from Baseline | -7.2 ± 22.65 | -10.4 ± 24.38 |
| Social Functioning Score: Baseline | 79.3 ± 25.37 | 78.8 ± 25.82 |
| Social Functioning Score: Change from Baseline | -13.7 ± 33.89 | -16.5 ± 34.78 |
| Fatigue Score: Baseline | 38.5 ± 25.44 | 33.8 ± 24.24 |
| Fatigue Score: Change from Baseline | 6.6 ± 26.41 | 12.3 ± 31.22 |
| Nausea/Vomiting Score: Baseline | 4.6 ± 11.39 | 4.7 ± 10.96 |
| Nausea/Vomiting Score: Change from Baseline | 2.4 ± 19.08 | 1.9 ± 15.00 |
| Pain Score: Baseline | 20.9 ± 25.55 | 19.4 ± 26.42 |
| Pain Score: Change from Baseline | 5.8 ± 30.36 | 6.8 ± 33.34 |
| Dyspnoea Score: Baseline | 25.4 ± 29.83 | 24.4 ± 28.90 |
| Dyspnoea Score: Change from Baseline | 5.9 ± 28.95 | 5.9 ± 29.46 |
| Insomnia Score: Baseline | 27.2 ± 27.96 | 25.7 ± 30.68 |
| Insomnia Score: Change from Baseline | 3.2 ± 34.32 | 4.6 ± 34.09 |
| Appetite Loss Score: Baseline | 23.4 ± 29.29 | 15.6 ± 23.99 |
| Appetite Loss Score: Change from Baseline | 4.6 ± 38.68 | 16.0 ± 34.03 |
| Constipation Score: Baseline | 14.7 ± 24.78 | 13.8 ± 22.47 |
| Constipation Score: Change from Baseline | 5.5 ± 29.56 | 5.1 ± 28.42 |
| Diarrhoea Score: Baseline | 7.6 ± 18.84 | 7.0 ± 16.75 |
| Diarrhoea Score: Change from Baseline | 3.0 ± 22.80 | 1.9 ± 27.65 |
| Financial Difficulties Score: Baseline | 14.2 ± 25.37 | 18.4 ± 26.76 |
| Financial Difficulties Score: Change from Baseline | 5.9 ± 27.03 | 7.4 ± 30.46 |
| QLQ-C30 Summary Score: Baseline | 77.9 ± 14.90 | 80.5 ± 15.08 |
| QLQ-C30 Summary Score: Change from Baseline | -6.1 ± 18.84 | -8.6 ± 17.75 |
Disease responses for HR MDS/CMML based on Modified IWG Response Criteria for MDS; for low-blast AML on Revised IWG Response Criteria for AML. Overall response=CR + PR for HR MDS/CMML and CR + CRi + PR for low-blast AML. CR for HR MDS/CMML: \<=5% myeloblasts with normal maturation of all bone marrow cell lines, \>=11 g/dL Hgb, \>=100\*10\^9/L pl, \>=1.0\*10\^9/L neutrophils,0% blasts in peripheral blood and PR: all CR criteria met except bone marrow blasts\>=50% decrease over pretreatment but still\>5%. For low-blast AML-CR: morphologic leukemia-free state, \>1.0\*10\^9 neutrophils,\>=100\*10\^9/L pl, transfusion independence, no residual evidence of extramedullary leukemia; CR with incomplete blood count recovery (CRi): fulfill CR criteria except residual neutropenia\<1.0\*10\^9/L or pl\<100\*10\^9/L; PR: all CR hematological values but\>=50% decrease in the percentage of blasts to 5% to 25% in bone marrow aspirate.
| Participants | Azacitidine 75 mg/m^2 | Pevonedistat 20 mg/m^2 + Azacitidine 75 mg/m^2 |
|---|---|---|
| OR: HR MDS/CMML Participants | 14 | 13 |
| OR: Low-blast AML Participants | 13 | 12 |
Event was defined as death or transformation to AML in participants with MDS or CMML, whichever occurred first. Transformation to AML was defined, according to World Health Organization (WHO) Classification as a participant having \>20% blasts in the blood or marrow and increase of blast count by 50%. Event was defined as death in participants with low-blast AML.
| months | Azacitidine 75 mg/m^2 | Pevonedistat 20 mg/m^2 + Azacitidine 75 mg/m^2 |
|---|---|---|
| Event-Free Survival in Participants Who Have TP53 Mutations, 17p Deletions, and/or Are Determined to be in an Adverse Cytogenetic Risk Group | 12.8 (8.44 to 14.32) | 14.6 (9.99 to 18.99) |
OS was calculated from date of randomization to the date of death due to any cause. Participants without documented death at the time of the analysis were censored as of the date the participant was last known to be alive.
| months | Azacitidine 75 mg/m^2 | Pevonedistat 20 mg/m^2 + Azacitidine 75 mg/m^2 |
|---|---|---|
| Overall Survival in Participants Who Have TP53 Mutations, 17p Deletions, and/or Are Determined to be in an Adverse Cytogenetic Risk Group | 12.8 (10.84 to 14.78) | 16.1 (11.40 to 20.24) |
Responses for HR MDS/CMML are based on Modified International Working Group (IWG) Response Criteria for MDS and for low-blast AML on Revised IWG Response Criteria for AML. Overall response=CR and PR for HR MDS/CMML and CR+CR with incomplete blood count recovery(CRi)+PR for low-blast AML. CR for HR MDS/CMML:\<=5% myeloblasts with normal maturation of all bone marrow cell lines,\>=11g/dL hemoglobin (Hgb),\>=100\*10\^9/L platelet (pl),\>=1.0\*10\^9/L neutrophils, 0% blasts in peripheral blood, and PR:all CR criteria met except bone marrow blasts \>=50% decrease over pretreatment but still \>5%. For low-blast AML-CR:morphologic leukemia-free state,\>1.0\*10\^9 neutrophils, \>=100\*10\^9/L pl, transfusion independence, no residual evidence of extramedullary leukemia;CRi:fulfill CR criteria except residual neutropenia \<1.0\*10\^9/L/thrombocytopenia (pl\<100\*10\^9/L); PR:all CR hematological values but\>=50% decrease in percentage of blasts to 5%-25% in bone marrow aspirate.
| Participants | Azacitidine 75 mg/m^2 | Pevonedistat 20 mg/m^2 + Azacitidine 75 mg/m^2 |
|---|---|---|
| Overall Response for HR MDS/CMML | 36 | 29 |
| Overall Response for Low-blast AML | 13 | 22 |
Collected over From first dose of study drug up to end of study (up to approximately 6.9 years). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Azacitidine 75 mg/m^2 | 153/220 (69.5%) | 145/220 (65.9%) | 207/220 (94.1%) |
| Pevonedistat 20 mg/m^2 + Azacitidine 75 mg/m^2 | 150/223 (67.3%) | 156/223 (70%) | 210/223 (94.2%) |
| Event | Azacitidine 75 mg/m^2 | Pevonedistat 20 mg/m^2 + Azacitidine 75 mg/m^2 |
|---|---|---|
| Febrile neutropeniaBlood and lymphatic system disorders | 35/220 | 43/223 |
| PneumoniaInfections and infestations | 25/220 | 33/223 |
| PyrexiaGeneral disorders | 16/220 | 6/223 |
| AnaemiaBlood and lymphatic system disorders | 10/220 | 13/223 |
| Septic shockInfections and infestations | 6/220 | 11/223 |
| SepsisInfections and infestations | 10/220 | 6/223 |
| ThrombocytopeniaBlood and lymphatic system disorders | 4/220 | 10/223 |
| CellulitisInfections and infestations | 1/220 | 9/223 |
| Urinary tract infectionInfections and infestations | 2/220 | 7/223 |
| Lower respiratory tract infectionInfections and infestations | 6/220 | 5/223 |
| Event | Azacitidine 75 mg/m^2 | Pevonedistat 20 mg/m^2 + Azacitidine 75 mg/m^2 |
|---|---|---|
| ConstipationGastrointestinal disorders | 90/220 | 82/223 |
| AnaemiaBlood and lymphatic system disorders | 82/220 | 78/223 |
| NeutropeniaBlood and lymphatic system disorders | 77/220 | 73/223 |
| NauseaGastrointestinal disorders | 63/220 | 78/223 |
| ThrombocytopeniaBlood and lymphatic system disorders | 74/220 | 71/223 |
| DiarrhoeaGastrointestinal disorders | 51/220 | 61/223 |
| PyrexiaGeneral disorders | 56/220 | 53/223 |
| VomitingGastrointestinal disorders | 46/220 | 51/223 |
| AstheniaGeneral disorders | 42/220 | 34/223 |
| FatigueGeneral disorders | 33/220 | 42/223 |
ITT Population included all participants who were randomized.
| Age, Continuous(years) | Azacitidine 75 mg/m^2 | Pevonedistat 20 mg/m^2 + Azacitidine 75 mg/m^2 | Total |
|---|---|---|---|
| Mean | 73.0 ± 8.22 | 73.0 ± 7.65 | 73 ± 7.93 |
| Sex: Female, Male(Participants) | Azacitidine 75 mg/m^2 | Pevonedistat 20 mg/m^2 + Azacitidine 75 mg/m^2 | Total |
|---|---|---|---|
| Female | 85 | 95 | 180 |
| Male | 142 | 132 | 274 |
| Ethnicity (NIH/OMB)(Participants) | Azacitidine 75 mg/m^2 | Pevonedistat 20 mg/m^2 + Azacitidine 75 mg/m^2 | Total |
|---|---|---|---|
| Hispanic or Latino | 26 | 31 | 57 |
| Not Hispanic or Latino | 188 | 189 | 377 |
| Unknown or Not Reported | 13 | 7 | 20 |
| Race (NIH/OMB)(Participants) | Azacitidine 75 mg/m^2 | Pevonedistat 20 mg/m^2 + Azacitidine 75 mg/m^2 | Total |
|---|---|---|---|
| American Indian or Alaska Native | 2 | 4 | 6 |
| Asian | 20 | 31 | 51 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 1 | 2 | 3 |
| White | 189 | 180 | 369 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 15 | 10 | 25 |
| Region of Enrollment(Participants) | Azacitidine 75 mg/m^2 | Pevonedistat 20 mg/m^2 + Azacitidine 75 mg/m^2 | Total |
|---|---|---|---|
| Australia | 3 | 4 | 7 |
| Belgium | 8 | 3 | 11 |
| Brazil | 10 | 18 | 28 |
| China | 2 | 0 | 2 |
| Czech Republic | 10 | 6 | 16 |
| Germany | 6 | 3 | 9 |
| Spain | 26 | 23 | 49 |
| France | 13 | 8 | 21 |
| United Kingdom | 1 | 3 | 4 |
| Greece | 30 | 28 | 58 |
| Israel | 6 | 6 | 12 |
| Italy | 14 | 9 | 23 |
| Japan | 12 | 26 | 38 |
| Korea, Republic of | 4 | 2 | 6 |
| Poland | 11 | 10 | 21 |
| Russia | 22 | 12 | 34 |
| Turkey | 5 | 5 | 10 |
| Canada | 2 | 7 | 9 |
| Mexico | 2 | 5 | 7 |
| United States of America | 40 | 49 | 89 |
| Height(centimeter (cm)) | Azacitidine 75 mg/m^2 | Pevonedistat 20 mg/m^2 + Azacitidine 75 mg/m^2 | Total |
|---|---|---|---|
| Mean | 167.59 ± 9.439 | 166.31 ± 10.098 | 166.95 ± 9.783 |
| Weight(kilogram (kg)) | Azacitidine 75 mg/m^2 | Pevonedistat 20 mg/m^2 + Azacitidine 75 mg/m^2 | Total |
|---|---|---|---|
| Mean | 77.65 ± 16.143 | 75.82 ± 15.996 | 76.73 ± 16.078 |
| Body Surface Area(meter square (m^2)) | Azacitidine 75 mg/m^2 | Pevonedistat 20 mg/m^2 + Azacitidine 75 mg/m^2 | Total |
|---|---|---|---|
| Mean | 1.89 ± 0.228 | 1.86 ± 0.233 | 1.88 ± 0.231 |
Showing the first 100 of 242 sites across 20 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.
Data sharing details ↗ · vivli.org
Ran from Nov 2017 to primary completion in May 2021, 42 months.
Results were first posted in Sep 2022, 1 year 3 months after primary completion.
Of 26 industry-sponsored phase 3 interventional studies under Myelodysplastic Syndromes, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 33 and three quarters within 52. This study's 42 months is close to that.
Counting every sponsor, half of 45 studies reached it within 50 months; a quarter within 38 and three quarters within 95.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Azacitidine